1) 国立がん研究センターがん情報サービス「がん登録・統計」http://ganjoho.jp/reg_stat/statistics/stat/summary.html
2) SEER Cancer Statistics Factsheets : Stomach Cancer. National Cancer Institute : Bethesda, MD, 2015 https://seer.cancer.gov/statfacts/html/stomach.html
3) Fuchs CS, et al : Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre. Lancet 383 : 31-39, 2014
5) GLOBOCAN Cancer Incidence and Mortality Worldwide, 2012
8) Watatsuki T, et al : Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer (abstract). J Clin Oncol 30 (suppl) : 4026, 2012
15) Thuss-Patience PC, et al : Survival advantage for irinotecan versus best supportive care as secondline chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47 : 2306-2314, 2011
22) Fuchs CS, et al : Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 : 31-39, 2014
24) 日本胃癌学会編 : 胃癌治療ガイドライン 医師用, 第4版, 金原出版, 東京, 2014